Were Analysts Bullish Boston Scientific Corporation (NYSE:BSX) This Week?

October 20, 2017 - By Dolores Ford

 Were Analysts Bullish Boston Scientific Corporation (NYSE:BSX) This Week?
Investors sentiment increased to 1.03 in Q2 2017. Its up 0.14, from 0.89 in 2017Q1. It is positive, as 41 investors sold Boston Scientific Corporation shares while 173 reduced holdings. 56 funds opened positions while 165 raised stakes. 1.22 billion shares or 0.64% less from 1.23 billion shares in 2017Q1 were reported.
Parkside Comml Bank Trust holds 0.01% or 824 shares. S&Co invested in 0.69% or 188,260 shares. State Of Tennessee Treasury Department owns 1.09M shares or 0.15% of their US portfolio. Quantitative Systematic Strategies Ltd Llc invested in 0.6% or 85,509 shares. Citigroup reported 0% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Exane Derivatives stated it has 0% in Boston Scientific Corporation (NYSE:BSX). Wealthfront Incorporated holds 0.01% or 28,656 shares. Lombard Odier Asset Mngmt (Europe) Limited has 18,259 shares for 0.03% of their portfolio. Zeke Capital Advsrs Ltd Liability Com has 9,027 shares for 0.05% of their portfolio. Intll Gp holds 0.04% or 430,629 shares in its portfolio. Chevy Chase Trust invested 0.16% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Sweden-based Livforsakringsbolaget Skandia Omsesidigt has invested 0.07% in Boston Scientific Corporation (NYSE:BSX). Victory Cap Management Inc has 23,600 shares for 0% of their portfolio. Fjarde Ap has invested 0.18% in Boston Scientific Corporation (NYSE:BSX). Sei has 0.6% invested in Boston Scientific Corporation (NYSE:BSX).

Since May 1, 2017, it had 0 insider buys, and 7 sales for $2.58 million activity. $408,778 worth of Boston Scientific Corporation (NYSE:BSX) shares were sold by Phalen Michael P.. $754,454 worth of Boston Scientific Corporation (NYSE:BSX) shares were sold by Ballinger Kevin J.. On Friday, June 9 the insider Pierce David A sold $379,736.

Boston Scientific Corporation (NYSE:BSX) Ratings Coverage

Among 27 analysts covering Boston Scientific Corporation (NYSE:BSX), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. Boston Scientific Corporation had 63 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, March 17 by Nomura. On Wednesday, October 28 the stock rating was maintained by Needham with “Buy”. The stock has “Hold” rating by TheStreet on Thursday, August 13. The company was maintained on Friday, July 29 by Needham. The stock of Boston Scientific Corporation (NYSE:BSX) has “Buy” rating given on Thursday, February 25 by SunTrust. RBC Capital Markets maintained the stock with “Buy” rating in Tuesday, May 30 report. The firm has “Hold” rating by Jefferies given on Friday, October 6. Needham maintained Boston Scientific Corporation (NYSE:BSX) rating on Thursday, June 22. Needham has “Buy” rating and $32 target. JP Morgan maintained Boston Scientific Corporation (NYSE:BSX) rating on Friday, July 29. JP Morgan has “Overweight” rating and $27 target. The stock of Boston Scientific Corporation (NYSE:BSX) has “Buy” rating given on Thursday, September 1 by Argus Research. Below is a list of Boston Scientific Corporation (NYSE:BSX) latest ratings and price target changes.

11/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $30.0 Maintain
06/10/2017 Broker: Jefferies Rating: Hold New Target: $28.0 Maintain
02/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $31.0 Maintain
25/09/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $32.0 Maintain
05/09/2017 Broker: Jefferies Rating: Hold New Target: $28.0 Maintain
01/09/2017 Broker: RBC Capital Markets Rating: Buy New Target: $31.0 Maintain
31/08/2017 Broker: BMO Capital Markets Rating: Buy New Target: $30.0 Maintain
31/08/2017 Broker: Needham Rating: Buy New Target: $32.0 Maintain
09/08/2017 Broker: Oppenheimer Rating: Hold Maintain
01/08/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $32.0000 Maintain

About 2.51M shares traded. Boston Scientific Corporation (NYSE:BSX) has risen 19.12% since October 20, 2016 and is uptrending. It has outperformed by 2.42% the S&P500.

Boston Scientific Corporation is a developer, maker and marketer of medical devices that are used in a range of interventional medical specialties. The company has market cap of $40.79 billion. The Firm offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It has a 52.09 P/E ratio. It operates in three divisions: Cardiovascular, Rhythm Management and MedSurg.

More important recent Boston Scientific Corporation (NYSE:BSX) news were published by: Nasdaq.com which released: “Will Recall Issue Hurt Boston Scientific (BSX) Q3 Earnings?” on October 18, 2017, also Prnewswire.com published article titled: “Boston Scientific To Webcast Conference Call Discussing Third Quarter 2017 …”, Prnewswire.com published: “Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and …” on October 04, 2017. More interesting news about Boston Scientific Corporation (NYSE:BSX) was released by: Prnewswire.com and their article: “Boston Scientific Announces Agreement to Acquire Apama Medical” with publication date: October 02, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.